OLD Mission Capital LLC, a renowned institutional investor in the medical equipment niche, has recently cut its stake in Hologic, Inc. by 63.1% during the fourth quarter. The move resulted in the sale of 3,019 shares worth $132,000 based on the company’s most recent disclosure with the Securities and Exchange Commission (SEC). Hologic is an American healthcare firm that researches, manufactures and distributes products necessary for women’s health care. These solutions include diagnostic products, medical imaging systems as well as surgical supplies.
The company operates through different segments: Breast Health, Diagnostics, GYN Surgical and Skeletal Health. The Breast Health Division offers a full range of innovative technologies including radiology equipment used in screening processes like digital mammography systems, molecular diagnostic tests for breast cancer diagnosis and sophisticated image-guided breast biopsy.
In other news from this iconic healthcare company, Director Scott T. Garrett recently sold 10,000 shares of Hologic’s stock at an average price of $79.72 per share in June 2021 amounting to a total transaction volume of $797,200. After this latest disposal exercise was concluded successfully on June 15th; Mr Garrett held a total amount of 57,039 shares valued approximately at $4,547.149.08.
Insider Essex D Mitchell also made headlines earlier this year when he disposed of 2,390 shares valued at $200,114.70 at an average price per share of $83 after completing the transaction on May 5th.
According to cash flow data provided by Reuters & Company profiled on Crunchbase website; while these transactions may have raised eyebrows among investors or market watchers outside America – they’re not uncommon practices where publicly traded firms disclose insider trades to investors worldwide via SEC filings as transparency seems to be at core value for all who do business here too!
Corporate insiders own only about 1.66% of the outstanding shares as at filing disclosed with the Securities and Exchange Commission. This information is valuable to investors who are interested in monitoring the activities of this firm’s directors, management team members and other major shareholders who have inside knowledge about how Hologic will perform in the foreseeable future.
Updated on: 26/02/2024
Debt to equity ratio: Strong Buy
Price to earnings ratio: Strong Buy
Price to book ratio: Strong Buy
We did not find social sentiment data for this stock
|Analyst / firm
|Cowen & Co.
Market Leading Healthcare Company Hologic Continues to Impress with Positive Investor Sentiment and Strong Earnings Reports
Hologic, Inc. is a leading developer, manufacturer, and supplier of diagnostics products, medical imaging systems, and surgical products dedicated to serving the healthcare needs of women. With a range of innovative solutions in breast health, diagnostics, GYN surgical, and skeletal health segments, Hologic is known for its commitment to improving patient outcomes through advanced technology and scientific research.
Recently, institutional investors have modified their holdings of HOLX with Romano Brothers AND Company acquiring a new stake in shares valued at around $25,000. Similarly, Whittier Trust Co., Salem Investment Counselors Inc., Lansing Street Advisors and Toth Financial Advisory Corp all followed suit by acquiring new stakes in shares of Hologic over the last few quarters with the percentage currently owned by institutional investors standing at an impressive 93.29%.
With such encouragement from institutional investors alone it’s no wonder Hologic has also received positive earnings reports from top investment companies like JPMorgan Chase & Co., Raymond James and Citigroup who provided a “Moderate Buy” rating on HOLX with an average target price of $86.00.
NASDAQ HOLX opened Monday morning at $81.46 showing steady improvement on the fifty-day moving average price of $81.56 and two-hundred-day moving average price of $80.35 respectively. The company has a potentially advantageous debt-to-equity ratio of 0.53 as well as maintaining both quick ratio (3.69) and current ratio (4.41) within good limits indicating above-average stability for traders.
In May 2017 the company reported earnings results for Q1 that beat analyst expectations with an earning per share figure sitting pretty at $1.06 compared to predicted estimates of $.88 reflecting positively on revenue postings which came in at just over what analysts had expected ($1.03 billion as opposed to initial estimates of $957 million). According to experts this bodes well for Hologic predictions with strong fiscal expectations of 3.89 earnings per share for this current year.
Overall, Hologic is an innovative and market leading organization with undeniable potential for continued growth in the healthcare industry. With solid balance sheets, positive investor sentiment and strong financial earnings reports it’s certainly an ideal pick up for buyers looking to invest in a highly-stable company.